Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1721-1726

  Yamada, Shusai ^a   Tabata, Chiharu ^a   Tabata, Rie ^b   Fukuoka, Kazuya ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

mesothelin; mesothelioma; tumor marker

Indexed keywords

ASBESTOS; CISPLATIN; MESOTHELIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURISY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; PLEURAL EFFUSION; PLEURAL NEOPLASMS;

EID: 80054947339     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.242     Document Type: Article

References (36)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603. (Pubitemid 41434638)
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
4. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;15:2736-40. (Pubitemid 11210245)
5. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study. Br J Cancer 2009;100:1175-83.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Sporn MB, Roberts AB. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
7. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002;29:82-96. (Pubitemid 34163539)
8. Stathopoulos GT. Translational advances in pleural malignancies. Respirology 2010;16:53-63.
9. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;9:136-40. (Pubitemid 26041483)
10. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodrí-guez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidem Biomar Prev 2009;18:646-50.
11. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
12. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-8.
13. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73. (Pubitemid 41434635)
14. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-22.
15. Ray M, Kindler HL. Malignant pleural mesothelioma: An update on biomarkers and treatment. Chest 2009;136:888-96.
16. Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 2000;33:405-10.
17. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001;119: 1138-42. (Pubitemid 32679442)
18. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6. (Pubitemid 37443528)
19. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, et al. Soluble mesothelin-related protein in an asbestosexposed population: The dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-7.
20. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437-44.
21. Pass HI, Wali A, Tang N, Ivanova A, Harbut M, Carbone M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72. (Pubitemid 350265805)
22. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, et al. Soluble mesothelin in effusions: A useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76. (Pubitemid 47056881)
23. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-24.
24. Tabata C, Tabata R, Hirayama N, Yasumitsu A, Yamada S, Murakami A, et al. All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice. Eur Respir J 2009;34:1159-67.
25. Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, van der Kwast TH, Eriksson A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alphareceptors. Oncogene 1991;6:2005-11. (Pubitemid 21924040)
26. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW, et al. Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorageindependent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44. (Pubitemid 24310376)
27. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57:3200-7.
28. Mórocz IA, Schmitter D, Lauber B, Stahel RA. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994;70:850-6. (Pubitemid 24331076)
29. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: An autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59:367-71. (Pubitemid 29048869)
30. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O'Byrne KJ. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-23. (Pubitemid 37433592)
31. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75. (Pubitemid 32266815)
32. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003; 104:603-10. (Pubitemid 36337260)
33. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, et al. Clinical significance of serum VEGF in malignant pleural mesothelioma. J Thorac Oncol 2010;5:479-83.
34. Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 2011; 105:137-42.
35. Tabata C, Hirayama N, Tabata R, Yasumitsu A, Yamada S, Murakami A, et al. A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J 2010;36:1099-105.
36. Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009;15:6511-8.